A study by researchers at the University of Wisconsin found that the use of Esbriet could prolong the lives of patients with IPF by slowing down the progression of lung damage. The drug was approved by the FDA as a therapy for IPF in 2014.
It also found that Esbriet can decrease lung function decline in some patients. In clinical trials, the forced vital capacity tests (FVC) which measure lung function only deteriorated by less than 10 percent for 47.9 percent of participants according to lungdiseasenews.com, leading to fewer deaths from the disease.
According to Genentech, there are some side effects associated with Esbriet, the drug can make skin sensitive to the sun and ultraviolet rays from sunlamps and tanning beds, it can also cause mild reactions such as tiredness, headaches, respiratory infections, sinus infections, dizziness, and weight loss. More serious risks include liver involvement and stomach problems such as diarrhea, constipation, abdominal pain, heartburn, indigestion, nausea, and vomiting.
Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?